Michael Yee RBC Capital
Vertex Pharm. (VRTX ) Buy Rating
June 25, 2014
10:50 EDT ICPT Intercept says FLINT data 'unlikely' to come in July
Rachel McMinn, Chief Strategy Officer of Intercept, said that after hearing last night from the National Instituteof Diabetes and Digestive and Kidney Diseases, the FLINT data is "unlikely" to come in July. The FLINT trial relates to the company's obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Tesla, BMW Rivalry Electrifying Luxury Car Market
Mannkind Afrezza FDA Panel
BY Adam Feuerstein
NEW YORK (TheStreet) -- Mannkind (MNKD_) By a 13-1 margin, experts on the panel voted to recommend the approval of Afrezza as a new insulin therapy for Type 1 diabetics. The same panel supported Afrezza use in Type 2 diabetics by a 14-0 vote.
Congratulations to Mannkind and its supporters, who were clearly right to believe in Afrezza's approval chances. The panel votes were overwhelmingly positive and should compel the FDA to approve the new in
haled insulin. Mannkind skeptics who believed FDA criticism of Afrezza would persuade the panel to rejectthe new insulin were wrong. I was one of those Afrezza non-believers, predicting a negative panel vote for both Type 1 and Type 2 diabetes. I was wrong.
Electric car groups eye collaboration over charging technology
By Henry Foy in London
Three of the world’s biggest electric-car makers are interested in collaborating on charging technology, following Tesla Motors’ decision to offer its patents to rivals in an attempt to promote the low-emission vehicles.Nissan and BMW, two of Tesla’s main competitors, are keen on talks with the US carmaker to co-operate on charging networks, sources at the three companies told the Financial Times
this is only down because of the lockup that occurred in May, Bull reversal in progress now.